{
    "nctId": "NCT05763472",
    "briefTitle": "Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation",
    "officialTitle": "Molecular Landscape Involved in the Onset of Breast Cancer in Patients With Germline BRCA-1/2 Mutations, During or After Therapy With Platinum-based Agents and/or PARP-inhibitors for Ovarian Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "BRCA-Associated Breast Carcinoma",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 10,
    "primaryOutcomeMeasure": "Breast somatic mutations",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent.\n* Age older than 18 years.\n* Germline BRCA1/2 mutation.\n* Histologically confirmed ovarian cancer treated with platinum-based chemotherapy and/or PARP inhibitors.\n* Histologically confirmed breast cancer occurred during or after therapy with platinum-based agents and/or PARP-inhibitors for ovarian cancer.\n* Availability of FFPE breast and ovarian tumor samples.\n\nExclusion Criteria:\n\n* Other malignancies in the last 2 years.\n* Prior chemotherapy or radiation therapy for other malignancies.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}